{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:31:18Z","timestamp":1792189878712,"version":"4.4.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve treatment efficacy is an open issue. We carried out the observational, prospective, multicenter Measure and See (MAS) study. Blood was collected 15 to 30\u00a0days after starting DOAC treatment in patients with AF who were followed-up for 1 year. Plasma samples were centralized for DOAC level measurement. Patients\u2019 DOAC levels were converted into drug\/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values (representing the distance of each value from the overall mean) by subtracting the DOAC-specific mean value from the original values and dividing by the standard deviation. Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. In total, 21 thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% of patients per year). Of 21 thrombotic events, 17 occurred in patients whose standardized activity levels were below the mean of each DOAC (0); the incidence was the highest (4.82% of patients per year) in patients whose standardized values were in the lowest class (\u22121.00 or less). Early measurement of DOAC levels in patients with AF allowed us to identify most of the patients who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012408","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:05:27Z","timestamp":1708700727000},"page":"1846-1856","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study"],"prefix":"10.1182","volume":"8","author":[{"given":"Sophie","family":"Testa","sequence":"first","affiliation":[{"name":"1Centro Emostasi e Trombosi, UO Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-9561","authenticated-orcid":false,"given":"Gualtiero","family":"Palareti","sequence":"additional","affiliation":[{"name":"2Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-7800","authenticated-orcid":false,"given":"Cristina","family":"Legnani","sequence":"additional","affiliation":[{"name":"2Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5704-953X","authenticated-orcid":false,"given":"Claudia","family":"Dellanoce","sequence":"additional","affiliation":[{"name":"1Centro Emostasi e Trombosi, UO Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-6159","authenticated-orcid":false,"given":"Michela","family":"Cini","sequence":"additional","affiliation":[{"name":"2Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-0031","authenticated-orcid":false,"given":"Oriana","family":"Paoletti","sequence":"additional","affiliation":[{"name":"1Centro Emostasi e Trombosi, UO Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciampa","sequence":"additional","affiliation":[{"name":"3Centro Emostasi, UOC Laboratorio Analisi, Ospedale S.G. Moscati, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-2046","authenticated-orcid":false,"given":"Emilia","family":"Antonucci","sequence":"additional","affiliation":[{"name":"2Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[{"name":"4Malattie Aterotrombotiche, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0025-1770","authenticated-orcid":false,"given":"Rossella","family":"Morandini","sequence":"additional","affiliation":[{"name":"1Centro Emostasi e Trombosi, UO Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5842-9036","authenticated-orcid":false,"given":"Maurizio","family":"Tala","sequence":"additional","affiliation":[{"name":"1Centro Emostasi e Trombosi, UO Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Chiarugi","sequence":"additional","affiliation":[{"name":"5UO di Analisi chimico cliniche, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-8201","authenticated-orcid":false,"given":"Rita Carlotta","family":"Santoro","sequence":"additional","affiliation":[{"name":"6Centro Emostasi e Trombosi, UO Emofilia e Patologie della Coagulazione, Dipartimento di Ematologia, Oncologia e Medicina Trasfusionale, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Iannone","sequence":"additional","affiliation":[{"name":"7UOSVD Sezione Trasfusionale, Ospedale Don Tonino Bello, Molfetta, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-2819","authenticated-orcid":false,"given":"Erica","family":"De Candia","sequence":"additional","affiliation":[{"name":"8UOSD Malattie Emorragiche e Trombotiche, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"9UOC Medicina Interna e Prevenzione dell\u2019Aterosclerosi, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-6531","authenticated-orcid":false,"given":"Elena Maria","family":"Faioni","sequence":"additional","affiliation":[{"name":"10Servizio Immunologia e Medicina Trasfusionale, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-1376","authenticated-orcid":false,"given":"Antonio","family":"Chistolini","sequence":"additional","affiliation":[{"name":"11UO Medicina Traslazionale e di Precisione, Dipartimento Medicina Interna e Specialit\u00e0 Mediche, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Pilar","family":"Esteban","sequence":"additional","affiliation":[{"name":"12UO Laboratorio Analisi, Dipartimento dei Servizi Diagnostici, Ospedale Oglio Po, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marietta","sequence":"additional","affiliation":[{"name":"13Struttura Complessa di Ematologia, Policlinico di Modena, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tripodi","sequence":"additional","affiliation":[{"name":"14Centro Emofila e Trombosi Angelo Bianchi Bonomi, presso la Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-5204","authenticated-orcid":false,"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[{"name":"15UOC Ematologia, Centro Malattie Emorragiche e Trombotiche, AULSS 8 Berica Ospedale S. Bortolo, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"12","key":"2024042218552556900_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024042218552556900_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024042218552556900_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024042218552556900_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024042218552556900_bib5","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"2024042218552556900_bib6","doi-asserted-by":"crossref","first-page":"E877","DOI":"10.9778\/cmajo.20200055","article-title":"Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study","volume":"8","author":"Durand","year":"2020","journal-title":"CMAJ Open"},{"issue":"3","key":"2024042218552556900_bib7","doi-asserted-by":"crossref","first-page":"e005894","DOI":"10.1161\/CIRCOUTCOMES.119.005894","article-title":"Effectiveness and safety of direct oral anticoagulants in relation to temporal changes in their use","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"2024042218552556900_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"2024042218552556900_bib9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"issue":"5","key":"2024042218552556900_bib10","doi-asserted-by":"crossref","first-page":"e0216831","DOI":"10.1371\/journal.pone.0216831","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study","volume":"14","author":"Poli","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"2024042218552556900_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/jgs.17884","article-title":"Oral anticoagulants and outcomes in adults \u226580 years with atrial fibrillation: a global federated health network analysis","volume":"70","author":"Harrison","year":"2022","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"2024042218552556900_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"2024042218552556900_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcph.288","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF","volume":"54","author":"Girgis","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"10","key":"2024042218552556900_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2019.12.060","article-title":"Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE trial","volume":"75","author":"Zeitouni","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"2024042218552556900_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"issue":"9984","key":"2024042218552556900_bib16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"2024042218552556900_bib17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/jth.13344","article-title":"To measure or not to measure direct oral anticoagulants before surgery or invasive procedures","volume":"14","author":"Tripodi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024042218552556900_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"Update of the international council for standardization in hematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"issue":"10","key":"2024042218552556900_bib19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"4","key":"2024042218552556900_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2024042218552556900_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64(3)","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2024042218552556900_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2024042218552556900_bib23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2024042218552556900_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024042218552556900_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics","volume":"137","author":"Testa","year":"2016","journal-title":"Thromb Res"},{"key":"2024042218552556900_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2019.01.008","article-title":"Edoxaban plasma levels in patients with non-valvular atrial fibrillation: inter and intra-individual variability, correlation with coagulation screening test and renal function","volume":"175","author":"Testa","year":"2019","journal-title":"Thromb Res"},{"issue":"5","key":"2024042218552556900_bib27","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjh.17899","article-title":"Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients","volume":"195","author":"Kampouraki","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2024042218552556900_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter- and intra-individual concentrations of direct oral anticoagulants: the KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024042218552556900_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review","volume":"62","author":"Edwina","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2024042218552556900_bib30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2024042218552556900_bib31","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024042218552556900_bib32","first-page":"88","article-title":"Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity","volume":"24","author":"Rizos","year":"2022","journal-title":"J\u00a0Stroke"},{"issue":"5","key":"2024042218552556900_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/jth.15677","article-title":"Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention","volume":"20","author":"Siedler","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024042218552556900_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00228-022-03280-8","article-title":"Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study","volume":"78","author":"Nos\u00e1\u013e","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2024042218552556900_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0039-1692700","article-title":"Preanalytical variables in coagulation testing: setting the stage for accurate results","volume":"45","author":"Gosselin","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2024042218552556900_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2017.05.005","article-title":"Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay","volume":"155","author":"He","year":"2017","journal-title":"Thromb Res"},{"issue":"2","key":"2024042218552556900_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ijlh.13159","article-title":"DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register","volume":"42","author":"Cini","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"2024042218552556900_bib38","article-title":"Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: results from DRIVING study","author":"de Fautereau-Vassel","year":"2023;46(1):120-127","journal-title":"Int J Lab Hematol"},{"issue":"446","key":"2024042218552556900_bib39","doi-asserted-by":"crossref","first-page":"94496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the sub distribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"2","key":"2024042218552556900_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin","volume":"15","author":"Gouin-Thibault","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024042218552556900_bib41","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jth.14541","article-title":"Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability","volume":"17","author":"Siguret","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024042218552556900_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/a-1981-1763","article-title":"Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban\/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients","volume":"123","author":"Foulon-Pinto","year":"2023","journal-title":"Thromb Haemost"},{"issue":"10","key":"2024042218552556900_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjmed.2021.06.003","article-title":"The impact of strong inducers on direct oral anticoagulant levels","volume":"134","author":"Sennesael","year":"2021","journal-title":"Am J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1846\/2222869\/blooda_adv-2023-012408-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1846\/2222869\/blooda_adv-2023-012408-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T14:56:06Z","timestamp":1713797766000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1846\/515072\/Thrombotic-events-associated-with-low-baseline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012408","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}